Wegovy® Pill — Important Safety Information

Important Safety Information for Wegovy® (semaglutide)

Warning: Risk of Thyroid C-Cell Tumors

• In studies with mice and rats, semaglutide (the active ingredient in Wegovy and Ozempic) caused thyroid tumors, including thyroid cancer. Tell your provider if you get a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath.
• Do not use Wegovy if you or any of your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

FDA-approved use

Wegovy is used to reduce excess body weight and maintain weight reduction long term, when used with a reduced calorie diet and increased physical activity, for adults with BMI ≥30 (obesity) or ≥27 with a weight-related comorbid condition. Wegovy is also used to reduce the risk of major adverse cardiovascular events (CV death, non-fatal MI or stroke) in adults with known CV disease and either obesity or overweight.

Limitations of Use: Wegovy should not be used in combination with other semaglutide-containing products or any other GLP-1 receptor agonist.

Who should not use Wegovy?

• Family or personal history of MTC or MEN 2
• Known allergic reaction to semaglutide

How should Wegovy be administered?

Self-administered as a subcutaneous injection in the stomach, thigh, or upper arm once a week on the same day every week, with or without food. Your EOS Health-affiliated provider will guide dose adjustments every four weeks.

What to tell your provider

Share all medications you take, including OTC, vitamins, and supplements. Watch out for interactions with insulin, sulfonylureas, other GLP-1s, and oral medications (Wegovy delays gastric emptying).

Share your full medical history, especially: diabetes, thyroid cancer, pancreatitis, kidney disease, diabetic retinopathy, depression, suicidal thoughts.

Pregnancy and breastfeeding

• Wegovy should not be used during pregnancy.
• Discontinue Wegovy at least 2 months before a planned pregnancy.
• Wegovy was found in the milk of lactating rats — tell your provider if you are breastfeeding.

Pregnancy registry: Contact Novo Nordisk at 1-877-390-2760 or visit wegovypregnancyregistry.com.

Most serious side effects

If experiencing a medical emergency, call 911.

• Thyroid C-cell tumors
• Acute pancreatitis: severe abdominal pain, possibly radiating to the back
• Acute gallbladder disease: upper-stomach pain, jaundice, fever, clay-colored stools
• Low blood sugar (hypoglycemia)
• Acute kidney injury from dehydration
• Serious allergic reactions
• Diabetic retinopathy complications
• Increased heart rate
• Suicidal behavior and ideation
• Never share a pen

Most common side effects

• Nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, dizziness, abdominal distension, belching, hypoglycemia in T2D, flatulence, gastroenteritis, GERD.

Report negative side effects: Contact Novo Nordisk at 1-833-934-6891 or FDA MedWatch at www.fda.gov/medwatch / 1-800-FDA-1088.

This information is not comprehensive. Please see the full Prescribing Information for complete safety information.